文献速递临床试验与 GCP基础与转化研究

体外循环心脏手术中个体化流量控制通气与常规压力控制通气的比较(FLOWVENTIN HEARTSURG):随机对照试验研究方案

Individualized flow-controlled versus conventional pressure-controlled ventilation in on-pump heart surgery (FLOWVENTIN HEARTSURG): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2023-03-16

FLOWVENTIN HEARTSURG为单中心随机平行组试验,计划比较择期体外循环心脏手术中围术期个体化流量控制通气(FCV组,n=70)与压力控制通气(PCV组,n=70,个体化呼气末正压、潮气量6-8 ml/kg预测体重)对术后炎症反应的影响,主要终点为体外循环后6小时血浆白细胞介素8水平。

要点

  • 择期体外循环心脏手术患者围术期分别接受个体化FCV或PCV通气。
  • 主要终点为体外循环后6小时血浆白细胞介素8水平,作为全身与肺部炎症的替代生物标志物。
  • 次要终点包括氧合指数等肺功能、术后肺部及肺外并发症、无全身炎症反应综合征天数、ICU及总住院时间。

核心结论

  • 作者假设围术期应用FCV较PCV可降低术后炎症反应。
  • 研究将FCV与当前最佳临床实践PCV在随机对照试验中比较。

研究设计与样本

  • FLOWVENTIN HEARTSURG为单中心、随机、平行组试验,设两个干预组。
  • PCV组n=70,采用个体化呼气末正压和潮气量6-8 ml/kg预测体重。
  • FCV组n=70,采用个体化呼气末正压和驱动压, resulting in a liberal tidal volume(原文此处为英文,意为导致宽松潮气量)。
  • 探索性子研究采用超声心动图评估围术期右心室功能参数、电阻抗断层成像评估围术期肺通气。
  • 试验注册于德国临床试验注册中心DRKS00018956,2020年6月12日注册(版本1),最后更新2022年8月22日(版本4)。

主要发现

  • 主要终点为体外循环后6小时血浆白细胞介素8水平,作为全身和肺部炎症的替代生物标志物。
  • 次要终点包括围术期氧合指数等肺功能、术后肺部及肺外并发症、无全身炎症反应综合征天数以及ICU和总住院时间。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In on-pump cardiac surgery, lungs are at high risk of periprocedural organ impairment because of atelectasis formation, ventilator-induced lung injury, and hyperinflammation due to the cardiopulmonary bypass which results in postoperative pulmonary complications in half of this patient population. The new ventilation mode flow-controlled ventilation (FCV) uniquely allows full control of ins- and expiratory airway flows. This approach reduces the mechanical power of invasive ventilation as a possible cause of ventilator-induced lung injury. The scope of FLOWVENTIN HEARTSURG is to compare perioperative individualized FCV with best clinical practice pressure-controlled ventilation (PVC) modes in patients with elective on-pump cardiac surgery procedures. We hypothesize that the postoperative inflammatory response can be reduced by the perioperative application of FCV compared to PCV. METHODS: FLOWVENTIN HEARTSURG is a single-center, randomized, parallel-group trial with two intervention arms: perioperative PCV modes (n = 70, PCV group) with an individualized positive end-expiratory pressure (PEEP) and a tidal volume of 6-8 ml/kg predicted bodyweight compared to perioperative FCV (n = 70, FCV group) with an individualized PEEP and driving pressure, resulting in a liberal tidal volume. As the primary study endpoint interleukin 8 plasma level is assessed 6 h after cardiopulmonary bypass as a surrogate biomarker of systemic and pulmonary inflammation. As secondary aims clinically relevant patient outcomes are analyzed, e.g., perioperative lung function regarding oxygenation indices, postoperative pulmonary and extra-pulmonary complications, SIRS-free days as well as ICU and total inpatient stays. As additional sub-studies with an exploratory approach perioperative right ventricular function parameters are assessed by echocardiography and perioperative lung aeration by electrical impedance tomography. DISCUSSION: Current paradigms regarding protective low tidal volume ventilation are consciously left in the FCV intervention group in order to reduce mechanical power as a determinant of ventilator-induced lung injury in this high-risk patient population and procedures. This approach will be compared in a randomized controlled trial with current best clinical practice PCV in FLOWVENTIN HEARTSURG. TRIAL REGISTRATION: German Clinical Trials Register DRKS00018956 . Registered on 12 June 2020 (Version 1), last update on 22 August 2022 (Version 4).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Becker S, Schnitzler R, Rembecki M, et al. Individualized flow-controlled versus conventional pressure-controlled ventilation in on-pump heart surgery (FLOWVENTIN HEARTSURG): study protocol for a randomized controlled trial. Trials. 2023. PMID: 36922825. doi:10.1186/s13063-023-07201-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。